Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yon Ho Choe

Showing results (21-30 of 158) with videos related to

Pageof 16
Sort By:
Scientific Reports|July 7, 2021
Author Correction: COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesityEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Pediatric Gastroenterology, Hepatology & Nutrition|July 21, 2016
Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center StudyWon Jae Song, Ben Kang, So Yoon Choi, et al.
Scientific Reports|March 22, 2021
COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesityEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Frontiers in Pediatrics|June 9, 2022
Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal ManifestationsYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
Frontiers in Immunology|November 17, 2022
Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remissionYiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, et al.
Therapeutic Advances in Gastroenterology|May 11, 2023
Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's disease patients with secondary loss of responseEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Gut and Liver|September 10, 2016
Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel DiseaseSo Yoon Choi, Ben Kang, Jee Hyun Lee, et al.
Gut and Liver|June 7, 2021
Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease PatientsEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
BMC Pediatrics|January 7, 2021
Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literatureYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
World Journal of Gastroenterology|September 26, 2022
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN studyYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
Pageof 16

Showing results (21-30 of 158) with videos related to

Sort By:
Pageof 16
Scientific Reports|July 7, 2021
Author Correction: COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesityEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Pediatric Gastroenterology, Hepatology & Nutrition|July 21, 2016
Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center StudyWon Jae Song, Ben Kang, So Yoon Choi, et al.
Scientific Reports|March 22, 2021
COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesityEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Frontiers in Pediatrics|June 9, 2022
Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal ManifestationsYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
Frontiers in Immunology|November 17, 2022
Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remissionYiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, et al.
Therapeutic Advances in Gastroenterology|May 11, 2023
Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's disease patients with secondary loss of responseEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
Gut and Liver|September 10, 2016
Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel DiseaseSo Yoon Choi, Ben Kang, Jee Hyun Lee, et al.
Gut and Liver|June 7, 2021
Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease PatientsEun Sil Kim, Yiyoung Kwon, Yon Ho Choe, et al.
BMC Pediatrics|January 7, 2021
Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literatureYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
World Journal of Gastroenterology|September 26, 2022
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN studyYiyoung Kwon, Eun Sil Kim, Yon Ho Choe, et al.
Pageof 16